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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does 
the use of intranasal oxytocin in the treatment of women with anorexia nervosa improve 
recognition of emotional expression compared to placebo?” 
STUDY DESIGN: A systematic review of three studies that were published in English between 
2014-2018.  
DATA SOURCES: Three randomized controlled trials (RCTs), two with a crossover design, 
that were published in peer-reviewed journals and found via PubMed. Articles were chosen 
based on pertinence to the clinical question.  
OUTCOMES MEASURED: Improvement in the ability to recognize facial expressions were 
measured through the Reading the Mind in the Eyes Test (RMET) and attentional bias scores 
from a visual probe test. Images for the visual probe test were gathered from the Korean Facial 
Expressions of Emotion collection.  
RESULTS: Kim et al. conducted a cross-over designed study that found increased vigilance to 
anger during administration of intranasal oxytocin. The calculated t-score was -2.847 (df = 30). 
This calculation is statistically significant with a p-value of 0.008. A study performed by 
Leppanen et al. found a mean change 土 standard deviation in accuracy on RMET as 78.83 土 
13.74 for women using a placebo. The change with regards to the intranasal oxytocin spray was 
81.77 土 10.67. This study did not include a calculation for statistical significance. Russell et al. 
found in an RCT that the mean change in accuracy in performance on the RMET was of 1.6 土
3.1 in the placebo group as contrasted to 0.1 土2.0 in the experimental group. This study also 
failed to provide a statistical significance calculation.  
CONCLUSION: Evidence presented in this review was inconclusive at determining whether 
intranasal oxytocin was effective at improving emotional recognition in women with anorexia 
nervosa. Statistical significance with a large treatment effect was shown in the study by Kim et 
al. in regards to increased vigilance of an angry expression. The studies by Leppanen et al. and 
Russell et al. did not provide a measure of statistical significance. Further research is needed to 
determine efficacy of intranasal oxytocin. 
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INTRODUCTION 
 Anorexia Nervosa (AN) is a psychiatric disorder in which patients have an intense fear of 
gaining weight leading to a restricted caloric intake, inability to accurately perceive their body 
shape, and using their weight as a means of self-appraisal. It is estimated that 9% of the 
American population will develop an eating disorder throughout their lifetime.1 While this does 
include other diagnoses such as bulimia nervosa and binge eating disorder, this constellation of 
disorders is the second most deadly mental illness, following opioid overdose.1 Due to the grave 
nature of anorexia nervosa, it is imperative that healthcare providers are able to effectively 
recognize the warning signs in patients, however, this has been ineffective. It is estimated that 
currently only 10% of patients with anorexia nervosa are actively seeking treatment.2 Even with 
this seemingly low treatment rate, the cost of eating disorders is $64.7 billion per year and the 
annual loss of well-being attributed to eating disorders is estimated at $326.5 billion.3  
The cause of AN is not well understood, but many models incorporate the potential 
factors of genetics, psychological wellness, personality traits, life experiences, and biologic 
properties. These factors interplay to cause severe distress in a patient’s life as seen by symptoms 
over a vast array of wellness determinants, including those in the physiological, behavioral, and 
social dimensions. Prominent indicators of anorexia nervosa may include weight loss, obsessive 
dieting, meal rituals, secondary amenorrhea, constipation, dizziness, cold intolerance, thinning 
hair, and social withdraw. In a 2018 study by Cardi et al.,4 it was found that while social 
difficulties are a feature of eating disorder pathology, they may also be a predisposing factor to 
the development of anorexia nervosa. Fear of judgement, lack of social competence, and 
submissive tendences in early childhood can be predictors of a future diagnosis.4 
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Once a patient with anorexia nervosa begins treatment, the standard regimen begins with 
weight stabilization through either an in-patient or out-patient program. Eating disorder treatment 
encompasses 23,560 inpatient hospitalizations per year in the United States.3 During this critical 
stage of treatment, patients are at risk of refeeding syndrome. This is where the body cannot 
handle an increased metabolic demand leading to edema, organ failure, muscle weakness, 
delirium, or death. Due to this potential complication, weight gain should be carefully monitored 
by a patient’s treatment team. Another vital aspect of treatment for AN is psychotherapy. 
Therapy should be aimed at creating a healthy mindset towards food and body image and can be 
accomplished through a vast array of techniques including cognitive behavioral therapy (CBT), 
family therapy, interpersonal therapy, or acceptance and commitment therapy.5 Adjunctive 
therapies may include nutritional counseling or pharmacotherapy.  
 Even with a multifaceted treatment approach, the relapse rate for anorexia nervosa is 
between 9-52%, the highest risk is within the first year of treatment.6 These high rates could be 
due to residual symptoms causing continued distress after completion of a treatment program.6 It 
is believed that the social difficulties that are causative and propagated through AN may be 
present after a seemingly successful treatment attempt.4 During psychotherapy patients may be 
able to improve some aspects of their social functioning, such as how to navigate anxiety 
surrounding eating in front of others. However, not every pathologic thought process can be 
corrected through psychotherapy and pharmacotherapy. For example, typical methods of 
treatment are unable to help a patient with anorexia nervosa recognize facial expressions. This 
social skill is vital in being able to navigate social scenarios. It is theorized that administration of 
a physiologic hormone may be able to accentuate nuanced social skills that psychotherapy 
cannot teach.7-9 Oxytocin is known as the social bonding hormone. Current literature suggests
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that levels of oxytocin in cerebrospinal fluid are lowered during the course of anorexia nervosa.7 
Preliminary studies have shown potential benefits in the use of oxytocin in adolescents with 
autism spectrum disorder.8 Intranasal administration of this hormone improves emotional 
recognition and facilitates trusting of strangers in this group.8 This paper evaluates three 
randomized controlled trials to investigate the use of intranasal oxytocin in the treatment of AN.    
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Does the use 
of intranasal oxytocin in the treatment of women with anorexia nervosa improve recognition of 
emotional expression compared to placebo?”  
METHODS 
This study incorporates three randomized controlled trials (RCTs) that were published in 
peer-reviewed journals. The studies were found through searching the PubMed database with the 
keywords of “anorexia nervosa” and “intranasal oxytocin”. Articles were selected based on 
relevance to the clinical question and use of patient-oriented outcomes (POEMS). Inclusion 
criteria consisted of studies published after 2009. Exclusion criteria consisted of studies 
published before 2009 and those that included patients with bulimia nervosa. Inclusion and 
exclusion criteria for each individual study can be found in Table 1.  
 The patient population included was women with anorexia nervosa. Studies focused on 
comparing an intranasal oxytocin intervention to an intranasal placebo spray. Each study had 
varying formulations for these intranasal sprays. The outcomes measured in all of the studies was 
improvement of a patient’s ability to recognize emotional expression. Recognition was assessed 
through the Reading the Mind in the Eyes Test (RMET) or based on attentional bias from a
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visual probe test. The statistics reported and used in this systematic review are t-scores, mean 
change from baseline, and mean 土 standard deviation.  
OUTCOMES MEASURED 
 The outcome measured in each of the three studies was ability to recognize facial 
expressions. The study performed by Kim et al. measured facial recognition based on attentional 
bias from a visual probe task.7 This task utilized images of faces modeling happiness, anger, or 
disgust from the Korean Facial Expressions of Emotions collection. Participants were shown a 
neutral and an emotionally expressive face side-by-side for 1,000 milliseconds. The pictures 
were then replaced by two visual dotted probes and participants had to press a button 
corresponding to which visual probe they saw first.7 Attentional bias was measured based on 
which probe the participant chose and how fast they reacted to the probe.7 Scores were calculated 
by subtracting mean reaction times for emotional stimuli from mean reaction times for neutral 
stimuli (Pneutral – Pemotional). This means that positive scores show increased attention to 
emotional stimuli, while negative scores are interpreted as avoidance of emotional stimuli.7 
The studies performed by Leppanen et al. and Russell et al. utilized a Reading the Mind 
in the Eyes Test (RMET).8,9 In each study, participants were shown 36 pictures of eyes 
portraying emotions and given the choice of four options to see if they could correctly identify 
the expression portrayed.8,9 The participants of these studies were then assessed based on 
response times and accuracy. It was theorized that a shorter reaction time for accurate guesses 
meant the patients were more familiar with the facial expression.8,9 Longer reaction times meant 
the patients had to think harder about the expression in front of them.    
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Table 1. Demographics and Characteristics of Included Studies  
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RESULTS 
 Kim et al. utilized a double-blinded, placebo controlled cross-over designed study to 
determine the effects of intranasal oxytocin on the attentional bias to facial expressions in 
women with anorexia nervosa.7 A total of 31 participants with anorexia nervosa, diagnosed by 
the DSM-IV criteria, were recruited between 2012-2013 from the Eating Disorder Clinic of 
Seoul Paik Hospital in South Korea.7 Exclusion criteria involved diagnoses that could further 
distort a patient’s social processing and can be found in Table 1. Patients were randomly 
assigned to receive either the intranasal oxytocin spray or an intranasal placebo via a Microsoft 
Excel program.7 In this study, patients self-administered the nasal spray under guidance of a 
researcher. The dot probe task was then completed within 45-minutes of administration.7 
Participants then returned within 4-7 days to complete their second trial with the other spray.7  
 In this study by Kim et al.7, attention was measured based on the speed with which the 
patient responded to each visual probe trial. The authors postulated that a faster response time 
would be seen if the patient had already been paying attention to the image that the probe 
replaced.7 Mean response times were recorded for each participant and outlying data beyond 2 
standard deviations from the average were removed for each patient.7 Statistical analysis was 
completed with t-scores and a calculated p-value. The angry expression had a t-score of -2.847 
with 30 degrees of freedom and a p-value of 0.008.7 Due to the p-value being less than 0.01, this 
shows that the change for the anger stimuli was statistically significant.7 The interpretation for 
this value is that patients with anorexia nervosa treated with intranasal oxytocin had increased 
vigilance for angry facial stimuli as compared to the avoidance of angry faces seen with the 
intranasal placebo trials.7 The happy and disgust stimuli did not have clinical significance due to 
low p-values of 0.868 and 0.120, respectively.7 The attentional bias for “happy” stimuli had a
  Kearney, Intranasal Oxytocin in AN 7 
 
resultant t-value of -0.168 with 30 degrees of freedom.7 The t-score for disgust stimuli was 1/602 
with 30 degrees of freedom.7 Results are listed in Table 2.  
Table 2. Attentional Bias Scores based on Emotional Expression (data from Kim et al.7) 
Emotion T-Score (df = 30) P-Value 
Happy -0.168 0.868 
Angry -2.847 0.008 
Disgust 1.602 0.120 
 
 A 2017 study conducted by Leppanen et al.8 investigated the efficacy of a dose of 
intranasal oxytocin in the interpretation of emotional expression in women with anorexia 
nervosa. Thirty women meeting the DSM-V diagnostic criteria for anorexia nervosa were 
recruited through the South London and Maudsley National Health Service.8 Exclusion criteria 
are listed in Table 1. The study design was a double-blinded, placebo-controlled cross-over 
design with randomization.8 Patients self-administered either the oxytocin or placebo intranasal 
spray and completed the Reading the Mind in the Eyes test (RMET) 15 minutes later.8 
Participants returned to complete the crossover after a two-week interval.8 
 The treatment effect for the Leppanen et al.8 study was considered small. This study 
utilized mean accuracy 土 standard deviation to assess treatment effect. For participants with 
anorexia nervosa, their accuracy percentage when calculated for the placebo intranasal spray was 
78.83 土 13.74.8 The values with regards to the oxytocin spray were 81.77 土 10.67.8 These 
results can be found in Table 3. There was no measure of precision calculated in regards to the
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desired outcome for the patients with anorexia nervosa. Therefore, statistical significance 
surrounding interpretation accuracy cannot be determined for this study.8 
Table 3. Performance on RMET in Patients with Anorexia Nervosa (data from Leppanen 
et al.8) 
 Drug Mean 土 SD 
Accuracy (%) Placebo 78.83 土 13.74 
 Oxytocin 81.77 土 10.67 
 
 In a 2018 randomized controlled trial, Russell et al.9 sought to investigate the long-term 
effects of intranasal oxytocin on the identification of emotional expression in women with 
anorexia nervosa. The study was conducted in two phases. Phase one was a six-week trial that 
recruited participants from December 2011 until May 2012.9 Phase two recruited patients from 
May 2013 to December 2013, but was shortened to four weeks for an unspecified reason.9 In 
total, 41 patients were recruited from a hospital-based Eating Disorder Unit at Northside Clinic 
in Sydney, Australia.9 All patients were receiving nutritional rehabilitation and met the DSM-IV 
diagnosis for anorexia nervosa.9 Pregnant women, suicidal patients, women with septal 
deviation, and other conditions listed in Table 1 were excluded from this study.9 The participants 
were blindly randomized to either the experimental or placebo group with a computer 
randomization software.9 Four women from the experimental group and four women from the 
placebo group were lost to follow-up.9 Russell et al.9 continued with a worst-case analysis by 
replacing the mean of the intervention group or the last case carried forward when able. 
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Patients in this study were tested with the RMET at baseline and at the conclusion of the 
trial.9 Throughout the experiment, women were given 2 doses of intranasal oxytocin or placebo 
spray per day.9 The doses were supervised by a nurse and vials were weighed after 
administration to ensure dose compliance.9 Statistical analysis was calculated with mean change 
in accuracy 土 standard deviation from baseline on the RMET. The placebo group had a 
resulting change of 1.6 土3.1 in contrast to the experimental oxytocin group whose mean change 
was 0.1 土2.0.9 Results can be found in Table 4. Despite these figures, Russell et al. did not 
calculate a precision value for this outcome measurement so statistical significance is unknown.9 
 Table 4. Outcome Measures for Baseline, Follow-Up, and Change over Time on the 
Reading Mind in the Eyes Test (data from Russell et al.9) 
Time Placebo (N = 17) Oxytocin (N = 16) Total (N = 33) 
Baseline 28.5 土3.8 30.3 土2.2 30.3 土2.5 
Follow-Up 30.2 土2.7 30.4 土2.2 29.7 土4.6 
Δ Change 1.6 土3.1 0.1 土2.0 0.9 土2.7 
 
DISCUSSION 
 This systematic review assessed the efficacy of intranasal oxytocin as an adjunctive 
therapy to target social functioning in the treatment of anorexia nervosa. Kim et al.7 found that 
doses of intranasal oxytocin increased patient’s vigilance to angry faces as compared to placebo 
with a p-value of 0.008 and a large treatment effect. The study performed by Leppanen et al.8 
suggests that oxytocin was effective in identification of emotional expression with higher 
accuracy percentages on the RMET test compared to placebo, 81.77 土 10.67 compared to 78.
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土 13.74. However, this study did not demonstrate statistical significance.8 The study conducted 
by Russell et al.9 suggests that the placebo group (1.6 土3.1) had a larger change in ability to 
recognize expressions correctly by the end of the trial as compared to the experimental group 
(0.1 土2.0), but statistical significance was again, not demonstrated.  
 A limitation found in all three studies used in this review was the use of adjunctive 
medications. There were participants in each of the three studies utilizing either antidepressant or 
antipsychotic medications. Three patients in the study by Kim et al.7 were taking a 20 mg 
fluoxetine prescription daily leading up to and throughout the trial. Half of the participants in the 
2017 study by Leppanen et al.8 were allowed to continue their psychotropic medications. Patients 
included in the study conducted by Russell et al.9 were allowed to stay on their medications due 
to ethical considerations. In this study, 59% of patients were taking an antidepressant and 66% of 
patients were prescribed an antipsychotic medication.9 
In the study by Kim et al.,7 patients were allowed to self-administer the nasal spray under 
supervision by a study clinician. This may have skewed the medication administration and 
delivery due to human error. The patients were not trained in how to use an intranasal spray 
correctly. A limitation found in the study conducted by Leppanen et al.8 was that some patients 
had completed the RMET assessment in prior studies. The patients with prior knowledge of the 
task had higher scores than those who were unfamiliar with the test.8 This undermines the study 
because prior experience seemed to have more of an effect on patient accuracy than the oxytocin 
treatment.  
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CONCLUSION 
 The evidence presented in this systematic review was inconclusive in determining if the 
use of intranasal oxytocin is effective at improving recognition of emotional expression in 
women with anorexia nervosa. While Kim et al.7 provided statistically significant evidence that a 
dose of intranasal oxytocin can increase vigilance to angry stimuli, the studies conducted by 
Leppanen et al.8 and Russell et al.9 did not provide statistical significance for the treatment group 
compared to placebo. More research is required to form a more precise conclusion. 
 Larger scale studies with statistical significance calculations are needed to further assess 
the efficacy of intranasal oxytocin as a treatment in anorexia nervosa. Future studies can begin to 
investigate the ideal dosing of intranasal oxytocin that will derive benefits for women with 
anorexia nervosa. These studies provided standardized dosing for all patients and weight-based 
dosing was not considered. Dosing schedules may also be examined in later studies to assess 
whether daily, twice daily, or weekly dosing would be more effective in seeing psychosocial 
benefits and how long therapy should be maintained. Other studies in this field can also examine 
the effects of utilizing both a psychotropic medication and intranasal oxytocin on psychosocial 
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